Immunogenicity testing of a novel engineered HIV-1 envelope Gp140 DNA vaccine construct

DNA and Cell Biology

Volumn 25, Issue 7, 2006, Pages 383-392

  Kumar, Sanjeev ^a   Yan, Jian ^a   Muthumani, Karuppiah ^a   Ramanathan, Mathura P ^a   Yoon, Hanna ^a   Pavlakis, George N ^b   Felber, Barbara K ^b   Sidhu, Maninder ^c   Boyer, Jean D ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; DNA VACCINE; ENVELOPE PROTEIN; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN E; PLASMID DNA; RECOMBINANT DNA; RECOMBINANT PROTEIN; VIRUS GLYCOPROTEIN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CODON; CONTROLLED STUDY; CROSS REACTION; CYTOPLASM; DRUG EFFICACY; ENVELOPE GENE; ENZYME LINKED IMMUNOSPOT ASSAY; EUKARYOTIC CELL; FEMALE; FLOW CYTOMETRY; GENE FUSION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION; STRUCTURAL GENE; VIRUS ISOLATION; VIRUS TYPING;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE; CROSS REACTIONS; DNA, VIRAL; EPITOPE MAPPING; FEMALE; GENE EXPRESSION; GENE PRODUCTS, ENV; GENES, ENV; GENETIC ENGINEERING; HIV ANTIGENS; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTE SUBSETS; TRANSFECTION; VACCINES, DNA;

EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33746796761     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.25.383     Document Type: Article

References (43)

1. ANDRE, S., SEED, B., EBERLE, J., SCHRAUT, W., BULTMANN, A., and HAAS, J. (1998). Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J. Virol. 72, 1497-1503.
2. BAROUCH, D.H., KUNSTMAN, J., KURODA, M.J. SCHMITZ, J.E., SANTRA, S., PEYERL, F.W., KRIVULKA, G.R., BEAUDRY, K., LIFTON, M.A., GORGONE, D.A., et al. (2000). Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 6869.
3. BERLIOZ-TORRENT, C., SHACKLETT, B., ERDTMANN, L. DELAMARRE, L., BOUCHAERT, L. SONIGO, P. DOKHELAR, M.C., and BENAROUS, R. (1999). Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J. Virol. 73, 1350-1357.
4. BOGE, M., WYSS, S., BONIFACINO, J.S., and THALI, M. (1998). A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J. Biol. Chem. 273, 15773-15777.
5. BORITZ, E., PALMER, B.E., and WILSON, C.C. (2004). Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol. 78, 12638-12646.
6. BOWER, J.F., SANDERS, K.L., and ROSS. T.M. (2005). C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. Curr. HIV Res. 3, 191-198.
7. BOYER, J.D., UGEN, K.E., CHATTERGOON, M., WANG, B., SHAH, A., AGADJANYAN, M., BAGARAZZI, M.L. JAVADIAN, A., CARRANO, R., CONEY, L., et al. (1997). DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. J Infect Dis. 176, 1501-1509.
8. BOYER, J.D., CHATTERGOON, M., MUTHUMANI, K., KUDCHODKAR, S., KIM, J., BAGARAZZI, M., PAVLAKIS, G., SEKALY, R., and WEINER, D.B. (2002). Next generation DNA vaccines for HIV-1. J. Liposome Res. 12, 137-142.
9. BU, Z., YE, L., VZOROV, A., TAYLOR, D., COMPANS, R.W., and YANG, C. (2004). Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain. Virology 328, 62-67.
10. BULTMANN, A., MURANYI, W., SEED, B., and HAAS, J. (2001). Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression. J. Virol. 75, 5263-5276
11. CHOI, M.J., KIM, J.H., and MAIBACH, H.I. (2006). Topical DNA vaccination with DNA/lipid based complex. Curr. Drug Deliv. 3, 37-45.
12. COONEY, E.L., MCELRATH, M.J., COREY, L., et al. (1993). Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. USA 90, 1882-1886
13. CORBET, S., VINNER, L., HOUGAARD, D.M., BRYDER, K., NIELSEN, H.V. and NIELSEN, C. and FOMSGAARD, A. (2000). Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res. Hum. Retroviruses 16, 1997-2008.
14. DUBAY, J.W., ROBERTS, S.J., HAHN B.H., and HUNTER, E. (1992). Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J. Virol. 66, 6616-6625.
15. FREED, E.O., and MARTIN, M.A. (1995). The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270, 23883-23886.
16. GABUZDA, D. H., LEVER, A., TERWILLIGER, E., and SODROSKI, J. (1992). Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 66, 3306-3315.
17. GAO, F., LI, Y., DECKER, J.M., PEYER, F.W., BIBOLLET-RUCHE, F., RODENBURG, C.M., CHEN, Y., SHAW, D.R., ALLEN, S., et al. (2003). Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice. AIDS Res. Hum. Retroviruses 19, 817-823.
18. GASCHEN, B., TAYLOR, J., YUSIM, K. FOLEY, B., GAO, F., LANG, D., NOVITSKY, V., HAYNES, B., HAHN, B.H., BHATTACHARYA, T., et al. (2002). Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360.
19. GRAHAM, B.S., and WRIGHT, P.F. (1995). Candidate AIDS vaccines. N. Engl. J. Med. 333, 1331-1339.
20. HAAS, J., PARK, E.C., and SEED, B. (1996). Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6, 315-324.
21. HAFFAR, O.K., NAKAMURA, G.R., and BERMAN, P.W. (1990). The carboxy terminus of human immunodeficiency virus type 1 gp160 limits its proteolytic processing and transport in transfected cell lines. J. Virol. 64, 3100-3103.
22. HERRERA, A.M., MUSACCHIO, A., FERNANDEZ, J.R., and DUARTE, C.A. (2000) Efficiency of erythropoietin's signal peptide for HIV (MN)-1 gp120 expression. Biochem. Biophys. Res. Commun. 273, 557-559.
23. HOWARTH, M., and ELLIOTTT, T. (2004). The processing of antigens delivered as DNA vaccines. Immunol Rev. 199, 27-39.
24. HU, S.L., FULTZ, P.N., MCCLURE, H.M., EICHBERG, J.W., THOMAS, E.K., ZARLING, J., SINGHAL, M.C., KOSOWSKI, S.G., SWENSON. R.B., and ANDERSON, D.C., et al. (1987). Effect of immunization with a vaccinia HIV env recombinant on HIV infection of chimpanzees. Nature 328, 721-723.
25. HUNTER, E., and SWANSTROM, R. (1990). Retrovirus envelope glycoproteins. Curr. Top. Microbiol. Immunol. 157, 187-253.
26. KANKI, P.J., HAMEL, D.J., SANKALE, J.L., HSIEH, C., THIOR, I., BARIN, F., WOODCOCK, S.A., GUEYE-NDIAYE, A., ZHANG, E., MONTANO, M., et al. (1999). Human immunodeficiency virus type 1 subtypes differ in disease progression. J. Infect. Dis. 179, 4218-4225.
27. KUMAR, S., AGGARWAL, P., VAJPAYEE, M., PANDEY, R.M., and SETH, P. (2006). Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India. Vaccine 24, 2585-2593.
28. KUTZLER, M.A., ROBINSON, T.M., CHATTERGOON, M.A., CHOO, D.K., CHOO, A.Y., CHOE, P.Y., et al. (2005). Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help J. Immunol. 175, 112-123.
29. LU, S., SANTORO, J.C., FULLER, D.H., HAYNES, J.R., and ROBINSON, H.L. (1995). Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209, 147-154.
30. MARSH, M., and PELCHEN-MATTHEWS, A. (2000). Endocytosis in viral replication. Traffic 1, 525-532.
31. MARTINEZ, V., COSTAGLIOLA, D., BONDUELLE, O., N'GO N., SCHNURIGER, A., THEODOROU, I., CLAUVEL, J.P., SICARD, D., AGUT, H., DEBRE, P., et al. (2005). Asymptomatiques, a long term study group: Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term non progression. J. Infect. Dis. 191, 2053-2063.
32. MCMICHAEL, A.J., and HANKE, T. (2003). HIV vaccines 1983-2003. Nat. Med. 9, 874-880.
33. MUTHUMANI, K., ZHANG, D., DAYES, N.S., HWANG, D.S., CALAROTA, S.A., CHOO, A.Y., BOYER, J.D., and WEINER, D.B. (2003). Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology 314, 134-146.
34. NABEL, G., MAKGOBA, W., and ESPARZA, J. (2002). HIV-1 diversity and vaccine development. Science 296, 2335.
35. QIU, J.T., LIU, B., TIAN, C., PAVLAKIS, G.N., and YU, X.F. (2000). Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J. Virol. 74, 5997-6005.
36. RAMANATHAN, M.P., CURLEY, P., III, SU, M., CHAMBERS, J.A., and WEINER, D.B. (2002). Carboxyl terminus of hVIP/mov34 is critical for HIV-1-Vpr interaction and glucocorticoid-mediated signaling. J. Biol. Chem. 277, 47854-47860.
37. TABERNERO, C., ZOLOTUKHIN, A.S., VALENTIN, A., PAVLAKIS, G.N., and FELBER, B.K. (1996). The posttranscriptional control element of the simian retrovirus type 1 forms an extensive RNA secondary structure necessary for its function. J. Virol. 70, 5998-6011.
38. UNAIDS. Report on the Global HIV/AIDS Epidemic. (2004). http://www.unaids.org.
39. WEST, J.T., WELDON, S.K., WYSS, S., LIN, X., YU, Q., THALI, M., and HUNTER, E. (2002). Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation. J. Virol. 76, 3338-3349.
40. WYATT, R., and SODROSKI, J. (1998). The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280, 1884-1888.
41. YANG, J.S., KIM, HWANG, D., CHOO, A.Y., DANG, K., MAGUIRE, H., KUDCHODKAR, S., RAMANATHAN, M.P., and WEINER, D.B. (2001). Induction of potent Th1-type immune responses from a novel DNA vaccine for west Nile virus New York isolate (WNV-NY 1999). J. Infect. Dis. 184, 809-816.
42. YANG, J.S., KIM, HWANG, D., CHOO, A.Y., DANG, K., MAGUIRE, H., KUDCHODKAR, S., RAMANATHAN, M.P. and WEINER, D.B. (2001). Induction of potent Th1-type immune responses from a novel DNA vaccine for west Nile virus New York isolate (WNV-NY 1999). J. Infect. Dis. 184, 809-816.
43. YE, L., BU, Z., VZOROV, A., TAYLOR, D., COMPANS, R.W., and YANG, C. (2004). Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: Role of the cytoplasmic domain. J. Virol. 78, 13409-13419.